TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20139793

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (60%-75% observed maximal HR) for > or =45 min.d‐1, 5 d.wk‐1 (n = 87)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching control group (n = 86)
Number of subjects: 173
Study: 18384230

Group type: EXPERIMENTAL
Intervention: Continue neuroleptic treatment for 12 months
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (discontinue treatment)
Number of subjects: 165
Study: 15690237

Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg/kg) added to the priming solution of the cardiopulmonary bypass circuit
Number of subjects: 50

Group type: COMPARATOR
Intervention: No steroids (nonsteroid group)
Number of subjects: 50
Study: 11975927

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10367039

Group type: EXPERIMENTAL
Intervention: Difference between armspan and height
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Grade II vertebral deformities
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Grade I vertebral deformities
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Correlation between armspan and height
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Mean difference in armspan and height between groups with or without grade II deformities
Number of subjects: 494
Study: 7551381

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (420 kcal daily high caloric supplement)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Nutritional intervention + Nandrolone decanoate (25 mg for women, 50 mg for men, injected intramuscularly on Days 1, 15, 29, and 43)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 217
Study: 1702132

Group type: EXPERIMENTAL
Intervention: rG‐CSF (2 micrograms/kg/day) for 14 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 963960

Group type: EXPERIMENTAL
Intervention: Peripheral venous occlusion of all four limbs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water immersion to the neck
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral venous occlusion during immersion
Number of subjects: 0
Study: 31784386

Group type: EXPERIMENTAL
Intervention: 42-mm glenosphere
Number of subjects: 82

Group type: COMPARATOR
Intervention: 38-mm eccentric glenosphere
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 30880937

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for COPD exacerbation
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: EXACT‐PRO assessment
Number of subjects: 295
Study: 28099408

Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) containing regimens
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) containing regimens
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1181
Study: 25827059

Group type: EXPERIMENTAL
Intervention: sodium phosphate and caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: sodium phosphate
Number of subjects: 12
Study: 23965255

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention for one year
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed intervention (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention sustained for one year after withdrawal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed intervention (control) during PF intervention
Number of subjects: 40
Study: 21518564

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 58
Study: 19841766

Group type: EXPERIMENTAL
Intervention: Air-particle abrasion with alumina particles (50 microm, Al2O3) + silanization
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 9.5% hydrofluoric acid (HF) for 90 s + silanization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (unrestored teeth)
Number of subjects: 60
Study: 17154781

Group type: EXPERIMENTAL
Intervention: Describing the task from the actor's perspective
Number of subjects: 0

Group type: COMPARATOR
Intervention: Describing the task from the observer's own perspective or another observer's perspective
Number of subjects: 0
Study: 15570142

Group type: EXPERIMENTAL
Intervention: 20 g of casein (CS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Whey proteins (WH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 23
Study: 11154543

Group type: EXPERIMENTAL
Intervention: Short-segment instrumentation with transpedicular grafting (TPG) (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Short-segment fixation alone (NTPG) (n = 10)
Number of subjects: 20
Study: 9135492

Group type: COMPARATOR
Intervention: Epirubicin 60 mg/m2/24 h (total dose for cycle 180 mg/m2) days 1, 2 and 3 (group A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2/24 h days 1, 2 and 3 and cisplatin 30 mg/m2/24 h days 2, 3, 4 and 5 (group B)
Number of subjects: 106
Study: 7703994

Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Open nephrectomy
Number of subjects: 16
Study: 3328681

Group type: EXPERIMENTAL
Intervention: Fentanyl 75 micrograms in 0.9% saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine 2 mg
Number of subjects: 20
Study: 30361470

Group type: EXPERIMENTAL
Intervention: Everolimus/reduced tacrolimus (EVR/rTAC)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Everolimus with tacrolimus discontinued (TAC Elimination)
Number of subjects: 716

Group type: COMPARATOR
Intervention: Standard tacrolimus (TAC Control)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Cumulative eGFR AUC
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Mean eGFR AUC
Number of subjects: 716
Study: 27152748

Group type: EXPERIMENTAL
Intervention: 800 mg IV-ibuprofen every 6 hours
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 206
Study: 26224300

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 115

Group type: COMPARATOR
Intervention: High-carbohydrate (HC) diet
Number of subjects: 115
Study: 23085508

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20807467

Group type: EXPERIMENTAL
Intervention: Low-Na high-K (LNAHK) diet
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: DASH-type diet
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 94
Study: 18462291

Group type: EXPERIMENTAL
Intervention: Intervention regime for early periodontal disease
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 109
Study: 16428570

Group type: EXPERIMENTAL
Intervention: 3 mg/kg lidocaine + 8 mg dexamethasone
Number of subjects: 75

Group type: COMPARATOR
Intervention: 3 mg/kg lidocaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: 3 mg/kg lidocaine for IVRA and 8 mg dexamethasone IV to the nonsurgical arm
Number of subjects: 75
Study: 15571445

Group type: EXPERIMENTAL
Intervention: Monetary incentives contingent on abstinence (CO +/‐ 4 ppm)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Noncontingent monetary incentives
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Contingent group
Number of subjects: 34
Study: 11705560

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 317

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 317
Study: 9354316

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for 3 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo once daily for 3 days
Number of subjects: 8
Study: 8131469

Group type: EXPERIMENTAL
Intervention: Computer-directed weaning system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Physician-controlled weaning
Number of subjects: 15
Study: 3592401

Group type: EXPERIMENTAL
Intervention: 3.0 ppm formaldehyde
Number of subjects: 38

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 38
Study: 31666831

Group type: COMPARATOR
Intervention: Standard Dressing (SD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspiration Drainage (AD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Negative-Pressure (NP)
Number of subjects: 60
Study: 28628356

Group type: EXPERIMENTAL
Intervention: Clips (GI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Silicone-resilient liner (GII)
Number of subjects: 30
Study: 26458964

Group type: EXPERIMENTAL
Intervention: Informed shared decision-making program (decision coaching by specialized nurses, evidence-based patient decision aid, training of physicians and nurses)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Informed shared decision-making program
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 192
Study: 22933814

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Standard AEDs (VPA‐ER)
Number of subjects: 1688
Study: 21471428

Group type: EXPERIMENTAL
Intervention: Self-management intervention program based on motivational interviewing
Number of subjects: 21
Study: 19481792

Group type: EXPERIMENTAL
Intervention: XP Bond (etch-and-rinse adhesive using moist bonding)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XP Bond (using dry bonding)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (self-etching adhesive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAA (as the sole biomimetic analog)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAA and PVPA (as dual biomimetic analogs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control medium (set Portland cement and simulated body fluid without biomimetic analog)
Number of subjects: 0
Study: 17944274

Group type: EXPERIMENTAL
Intervention: Live, attenuated intranasal influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonals for respiratory syncytial virus (RSV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel inhibitors for influenza, RSV, and rhinovirus infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiviral therapies and vaccine strategies
Number of subjects: 0
Study: 15081561

Group type: EXPERIMENTAL
Intervention: Red palm olein (RPO)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Palm olein (POL)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sunflower oil (SFO)
Number of subjects: 59
Study: 11268947

Group type: EXPERIMENTAL
Intervention: MFL (Methotrexate 100 mg/m2 and 5-FU 600 mg/m2 followed by leucovorin rescue)
Number of subjects: 55

Group type: COMPARATOR
Intervention: UFT-MMC (Mitomycin C 12 mg/m2 intraoperatively and 6 mg/m2 every other week for 2 months, oral UFT 375 mg/m2/day for 3 years or longer)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MFL (Methotrexate and 5-FU followed by leucovorin rescue)
Number of subjects: 55

Group type: COMPARATOR
Intervention: UFT-MMC (Mitomycin C and UFT)
Number of subjects: 55
Study: 9917606

Group type: EXPERIMENTAL
Intervention: Cementless taper design femoral components
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Cemented femoral implants
Number of subjects: 1000
Study: 7819596

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (100 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (250 mg/kg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (400 mg/kg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 3278367

Group type: EXPERIMENTAL
Intervention: 10 g apple pectin USP powder twice daily
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine at night
Number of subjects: 83

Group type: COMPARATOR
Intervention: One tablet matching ranitidine placebo at night
Number of subjects: 83
Study: 31801404

Group type: EXPERIMENTAL
Intervention: Broadband light (BBL) treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 25
Study: 31359829

Group type: EXPERIMENTAL
Intervention: Romiplostim administration after transplantation
Number of subjects: 93
Study: 29361348

Group type: EXPERIMENTAL
Intervention: Plinth-based trunk exercise regime
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Swiss ball-based trunk exercise regime
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard physiotherapy (Control)
Number of subjects: 108
Study: 27002107

Group type: EXPERIMENTAL
Intervention: FOLFOX plus cetuximab (arm A)
Number of subjects: 153

Group type: COMPARATOR
Intervention: FOLFOX (arm B)
Number of subjects: 153
Study: 25394434

Group type: EXPERIMENTAL
Intervention: Cellulose dialyzer
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Polysulfone dialyzer
Number of subjects: 73
Study: 23778995

Group type: EXPERIMENTAL
Intervention: rhTPO (300 IU/kg Qd)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (conventional systemic therapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 20412149

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 114

Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bispectral index
Number of subjects: 114
Study: 18258383

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional radiotherapy (historical control)
Number of subjects: 23
Study: 17058828

Group type: EXPERIMENTAL
Intervention: Ginaton 1 mg/kg by intravenous dripping before open heart for CPB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 12954825

Group type: EXPERIMENTAL
Intervention: Proximally porous‐coated titanium stem with hydroxyapatite coating
Number of subjects: 50

Group type: COMPARATOR
Intervention: Proximally porous‐coated titanium stem without hydroxyapatite coating
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 10720289

Group type: EXPERIMENTAL
Intervention: Cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for two cycles (total dose 0.7 mg/kg)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for six cycles (total dose 2.1 mg/kg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 8645512

Group type: EXPERIMENTAL
Intervention: Omeprazole: an initial bolus of 80 mg + perfusion of 3.3 mg/h
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Omeprazole: an initial bolus of 80 mg + 40 mg/12 h
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Omeprazole: 40 mg/8 h
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ranitidine: perfusion of 12.5 mg/h
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ranitidine: 50 mg/4 h
Number of subjects: 47
Study: 1511370

Group type: EXPERIMENTAL
Intervention: Frequent follow-up (1 and 3 years after initial polypectomy)
Number of subjects: 9112

Group type: COMPARATOR
Intervention: Less frequent follow-up (3 years)
Number of subjects: 9112
Study: 6744886

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29719093

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for mood and behavior dysregulation (IPT‐MBD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 19
Study: 26621326

Group type: EXPERIMENTAL
Intervention: Caffeine fasting
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo fasting
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caffeine meal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo meal
Number of subjects: 60
Study: 24873996

Group type: EXPERIMENTAL
Intervention: Pregnant women with PCOS
Number of subjects: 150
Study: 21984039

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy with BiClamp(®) and multimodal anaesthesia (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with spinal anaesthesia (group B)
Number of subjects: 60
Study: 19684633

Group type: EXPERIMENTAL
Intervention: Total body MRI-governed involved compartment irradiation (ICI) followed by high-dose chemotherapy (HDC) and stem cell rescue (SCR)
Number of subjects: 37

Group type: COMPARATOR
Intervention: European Intergroup Cooperative Ewing Sarcoma Study-92 (EICESS-92) protocol
Number of subjects: 37
Study: 18929202

Group type: EXPERIMENTAL
Intervention: Short-arm cast extended to the proximal interphalangeal joint with a 3-point mold (MCP-ext)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Short-arm cast with volar outriggers (SAC-VOR)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: MCP-ext
Number of subjects: 81

Group type: COMPARATOR
Intervention: SAC-VOR
Number of subjects: 81
Study: 15925814

Group type: EXPERIMENTAL
Intervention: PEFG regimen (40 mg/m2 cisplatin, 40 mg/m2 epirubicin, 600 mg/m2 gemcitabine, 200 mg/m2 fluorouracil)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Gemcitabine alone (1000 mg/m2)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PEFG regimen
Number of subjects: 99

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 99
Study: 12689974

Group type: EXPERIMENTAL
Intervention: Interleukin-2 receptor antibodies
Number of subjects: 1858
Study: 10646048

Group type: EXPERIMENTAL
Intervention: Racecadotril (100 mg three times daily)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Loperamide (2 mg after each diarrhoeic stool)
Number of subjects: 157
Study: 8906513

Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: DBP and SBP levels
Number of subjects: 885
Study: 1905051

Group type: EXPERIMENTAL
Intervention: Skills-building intervention (five sessions of small groups)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 91
Study: 7201837

Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) administered intravenously (i.v.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) administered orally (p.o.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) administered i.v. in smokers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) administered i.v. in non-smokers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/kg antipyrine (phenazone) in smokers
Number of subjects: 12
Study: 31909448

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30665829

Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine/rosuvastatin (80 mg/10 mg plus 20 mg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: telmisartan/rosuvastatin (80 mg plus 20 mg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: telmisartan/amlodipine (80 mg/10 mg)
Number of subjects: 148
Study: 30544421

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (NMB)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Moderate neuromuscular block (NMB)
Number of subjects: 196
Study: 27502582

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg to 90 mg escalation
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg steady dose
Number of subjects: 1404
Study: 24149215

Group type: EXPERIMENTAL
Intervention: Peer-led HIV intervention
Number of subjects: 0
Study: 22238577

Group type: EXPERIMENTAL
Intervention: L-DOPA (0, 100/25, 200/50 mg, Sinemet)
Number of subjects: 0
Study: 18199500

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg daily for 8 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17187585

Group type: EXPERIMENTAL
Intervention: Fatty meal (800 kcal, 60% calories from fat)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (800 kcal)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (11 participants)
Number of subjects: 21
Study: 15121931

Group type: EXPERIMENTAL
Intervention: Parenteral glutamine supplementation
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Control (TrophAmine)
Number of subjects: 1433
Study: 28692301

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (3.5 mg or 140,000 IU biweekly for 8 weeks)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 10626290

Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade (LHRH agonists combined with antiandrogens)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LH-RH analogues alone or in combination with antiandrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early androgen deprivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant or adjuvant use of LH-RH analogues
Number of subjects: 0
Study: 8791042

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 132
Study: 1560168

Group type: EXPERIMENTAL
Intervention: Antigen challenge (0.004 to 100 PNU/ml)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Antigen challenge in nonatopic control subjects
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High dose antigen challenge (>= 1 PNU/ml) in atopic subjects
Number of subjects: 44
Study: 6585529

Group type: EXPERIMENTAL
Intervention: Amalgam restorations made of five conventional composition alloys and one high copper alloy.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amalgam restorations made by two operators.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amalgam restorations after 1 year.
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Amalgam restorations over 5 years.
Number of subjects: 57
Study: 31320490

Group type: EXPERIMENTAL
Intervention: Triple tracer (blue dye, indocyanine green, and Tc99)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Double tracer (indocyanine green and Tc99)
Number of subjects: 157
Study: 29903674

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) co-administered with 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Sequential administration of PPSV23 followed by RZV
Number of subjects: 865